Is treating high-risk prostate cancer with trimodality therapy safe for a patient who remains on anti-PD1 therapy for metastatic melanoma?

More important question is do we need to treat patient with triple modality for high risk disease if they have metastatic melanoma as outcome would be dictated by metastatic disease